What is VKTX's five-year median P/S?

There are not enough weekly readings yet for a five-year median P/S.

Does a low historical rank mean a stock is a buy?

No. The rank compares VKTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Viking Therapeutics Inc (VKTX) P/S ratio history

Health Care

$25.36

Latest weekly close · Market cap $3.0B

Viking Therapeutics' P/S is not ranked because its revenue over the last twelve months is too small to compare (as of Oct 29, 2026).

No P/E: earnings over the last twelve months are negative.
No EV/Sales: recent financial data is missing.
No EV/EBITDA: recent financial data is missing.

No P/S chart for VKTX right now

VKTX has no weekly P/S history to chart yet.

P/S

n/mnot ranked

No P/S rank: revenue is too small to compare.

Growth, last 12 months vs the year before

Revenue: n/m
EPS: n/m

Health Care peers on P/S

Each percentile compares a stock with its own last five years.

Compare VKTX with peers

Health Care peers of VKTX on P/S
Stock	P/S	Versus its own history	5-year percentile
ABBVAbbVie	7.9×	Historically high	100
AMGNAmgen	6.5×	Historically high	99
ARWRArrowhead Pharmaceuticals Inc	12.9×	Within its usual range	37
BBIOBridgebio Pharma Inc	19.4×	Below its usual range	19
BIIBBiogen	3.5×	Above its usual range	73

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on VKTX

No articles about VKTX yet. How valuation percentiles work

Loading peers and related research…

About this history

What is VKTX's current P/S?: Viking Therapeutics' P/S is not ranked because its revenue over the last twelve months is too small to compare (as of Oct 29, 2026).
What is VKTX's five-year median P/S?: There are not enough weekly readings yet for a five-year median P/S.
Does a low historical rank mean a stock is a buy?: No. The rank compares VKTX only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.